{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:17:41Z","timestamp":1792729061744,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["CT116855"],"award-info":[{"award-number":["CT116855"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["CT116853"],"award-info":[{"award-number":["CT116853"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["208657"],"award-info":[{"award-number":["208657"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["MEA117113"],"award-info":[{"award-number":["MEA117113"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["MEA117106"],"award-info":[{"award-number":["MEA117106"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Disease stability in chronic obstructive pulmonary disease (COPD) is a low disease activity state proposed as a treatment target.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Characterize COPD stability as a composite endpoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Post hoc analyses were carried out on IMPACT and FULFIL (fluticasone furoate\/umeclidinium\/vilanterol [FF\/UMEC\/VI] vs dual therapies) and MATINEE\/METREX\/METREO (mepolizumab added onto triple therapy). Stability was defined as \u201cno moderate\/severe exacerbations and no worsening from baseline in COPD Assessment Test (CAT) and FEV1.\u201d We assessed whether achieving stability at week 28 was prognostic of subsequent outcomes (time to first on-treatment moderate\/severe exacerbation and time to all-cause mortality [ACM]) after week 28 (IMPACT). Bayesian joint modeling evaluated the probability of achieving stability (IMPACT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Stability was achieved with FF\/UMEC\/VI by 22% of patients in IMPACT (week 52) and by 46% of patients in FULFIL (week 24); stability was achieved with mepolizumab\u2009+\u2009triple therapy by 18% of patients in MATINEE\/METREX\/METREO (week 52). Patients were more likely to achieve stability with triple vs dual therapy and with mepolizumab vs placebo. Many individuals achieving stability had clinically meaningful improvements in CAT and FEV1. Patients achieving stability at week 28 (vs patients who were not stable) had a 45.7% reduction in the risk of moderate\/severe exacerbations and a 51.7% reduction in the risk of ACM after week 28. Bayesian joint modeling demonstrated a mean (SD) posterior probability of stability: 25.60% (0.66) at week 52 (FF\/UMEC\/VI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data provide further evidence for disease stability as an achievable COPD treatment target that predicts long-term clinical benefits in exacerbations and mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajrccm\/aamag292","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:46:33Z","timestamp":1781178393000},"page":"2036-2049","source":"Crossref","is-referenced-by-count":4,"title":["Defining disease stability in chronic obstructive pulmonary disease: evidence from phase 3 clinical trials"],"prefix":"10.1093","volume":"212","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8918-7075","authenticated-orcid":false,"given":"Dave","family":"Singh","sequence":"first","affiliation":[{"name":"Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester, Manchester University NHS Foundation Trust , Manchester,","place":["United Kingdom"]},{"name":"Medicines Evaluation Unit, an IQVIA business , Manchester,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6516-3172","authenticated-orcid":false,"given":"Rianne","family":"Stacey","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, General Medicines, GSK , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2009-4406","authenticated-orcid":false,"given":"David M G","family":"Halpin","sequence":"additional","affiliation":[{"name":"University of Exeter Medical School, University of Exeter The College of Medicine & Health, , Exeter,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-4497","authenticated-orcid":false,"given":"Surya P","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham , Birmingham, AL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0150-0333","authenticated-orcid":false,"given":"Jodie","family":"Crawford","sequence":"additional","affiliation":[{"name":"Development Biostatistics, GSK , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1443-5999","authenticated-orcid":false,"given":"Thomas","family":"Drury","sequence":"additional","affiliation":[{"name":"Development Biostatistics, GSK , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Di Boscio","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, General Medicines, GSK , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Kolterer","sequence":"additional","affiliation":[{"name":"Specialty Medicines, GSK , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9095-4419","authenticated-orcid":false,"given":"MeiLan K","family":"Han","sequence":"additional","affiliation":[{"name":"University of Michigan Division of Pulmonary and Critical Care, , Ann Arbor, MI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"2026091717071523600_aamag292-B1","author":"Global Initiative for Chronic Obstructive Lung Disease","year":"2026"},{"key":"2026091717071523600_aamag292-B2","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1164\/rccm.202406-1254CI","article-title":"Is disease stability an attainable chronic obstructive pulmonary disease treatment goal?","volume":"211","author":"Singh","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026091717071523600_aamag292-B3","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.2147\/COPD.S419056","article-title":"Novel anti-inflammatory approaches to COPD","volume":"18","author":"Cazzola","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026091717071523600_aamag292-B4","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1056\/NEJMra1900475","article-title":"Update on the pathogenesis of chronic obstructive pulmonary disease","volume":"381","author":"Agusti","year":"2019","journal-title":"N Engl J Med"},{"key":"2026091717071523600_aamag292-B5","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.chest.2025.03.029","article-title":"Forecasting the global economic and health burden of COPD from 2025 through 2050","volume":"168","author":"Boers","year":"2025","journal-title":"Chest"},{"key":"2026091717071523600_aamag292-B6","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/S0140-6736(24)00685-8","article-title":"Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021","volume":"403","author":"GBD 2021 Forecasting Collaborators","year":"2024","journal-title":"Lancet"},{"key":"2026091717071523600_aamag292-B7","doi-asserted-by":"publisher","first-page":"e069679","DOI":"10.1136\/bmj-2021-069679","article-title":"Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019","volume":"378","author":"Safiri","year":"2022","journal-title":"BMJ"},{"key":"2026091717071523600_aamag292-B8","author":"Brusselle","year":"2025"},{"key":"2026091717071523600_aamag292-B9","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.chest.2025.10.037","article-title":"Clinical outcomes in patients with COPD with disease stability","volume":"169","author":"Son","year":"2026","journal-title":"Chest"},{"key":"2026091717071523600_aamag292-B10","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1186\/s12913-024-11370-9","article-title":"Patient perspectives on the Tailored intervention for Anxiety and Depression Management in COPD (TANDEM): a qualitative evaluation","volume":"24","author":"Sohanpal","year":"2024","journal-title":"BMC Health Serv Res"},{"key":"2026091717071523600_aamag292-B11","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1007\/s12325-024-02982-y","article-title":"Striving for stability in patients with COPD: a new way forward?","volume":"41","author":"Han","year":"2024","journal-title":"Adv Ther"},{"key":"2026091717071523600_aamag292-B12","author":"Brooke","year":"2024"},{"key":"2026091717071523600_aamag292-B13","author":"Halpin","year":"2025"},{"key":"2026091717071523600_aamag292-B14","author":"Halpin","year":"2024"},{"key":"2026091717071523600_aamag292-B15","author":"Halpin","year":"2024"},{"key":"2026091717071523600_aamag292-B16","author":"Han","year":"2025"},{"key":"2026091717071523600_aamag292-B17","author":"Singh","year":"2025"},{"key":"2026091717071523600_aamag292-B18","author":"Han","year":"2026"},{"key":"2026091717071523600_aamag292-B19","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"key":"2026091717071523600_aamag292-B20","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","article-title":"FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease","volume":"196","author":"Lipson","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026091717071523600_aamag292-B21","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"key":"2026091717071523600_aamag292-B22","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype","volume":"392","author":"Sciurba","year":"2025","journal-title":"N Engl J Med"},{"key":"2026091717071523600_aamag292-B23","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1183\/09031936.00102509","article-title":"Development and first validation of the COPD Assessment Test","volume":"34","author":"Jones","year":"2009","journal-title":"Eur Respir J"},{"key":"2026091717071523600_aamag292-B24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S2213-2600(14)70001-3","article-title":"Minimum clinically important difference for the COPD Assessment Test: a prospective analysis","volume":"2","author":"Kon","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026091717071523600_aamag292-B25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1081\/copd-200053377","article-title":"Minimal clinically important differences in COPD lung function","volume":"2","author":"Donohue","year":"2005","journal-title":"COPD"},{"key":"2026091717071523600_aamag292-B26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1164\/rccm.201310-1863PP","article-title":"Minimal clinically important differences in pharmacological trials","volume":"189","author":"Jones","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026091717071523600_aamag292-B27","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2147\/COPD.S29868","article-title":"Assessment of COPD wellness tools for use in primary care: an IPCRG initiative","volume":"7","author":"Cave","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026091717071523600_aamag292-B28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1081\/copd-200050513","article-title":"St. George\u2019s respiratory questionnaire: MCID","volume":"2","author":"Jones","year":"2005","journal-title":"COPD"},{"key":"2026091717071523600_aamag292-B29","doi-asserted-by":"crossref","DOI":"10.1201\/b17116","volume-title":"Dependence Modeling With Copulas","author":"Joe","year":"2014"},{"key":"2026091717071523600_aamag292-B30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/pst.1852","article-title":"Bayesian joint modelling of benefit and risk in drug development","volume":"17","author":"Costa","year":"2018","journal-title":"Pharm Stat"},{"key":"2026091717071523600_aamag292-B31","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1164\/rccm.202501-0290LE","article-title":"Reply to Hsiao and Chen: refining the concept of disease stability in chronic obstructive pulmonary disease: bridging complexity and clinical practice","volume":"211","author":"Singh","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026091717071523600_aamag292-B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2019.12.014","article-title":"Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life","volume":"73","author":"Hurst","year":"2020","journal-title":"Eur J Intern Med"},{"key":"2026091717071523600_aamag292-B33","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.arbres.2016.08.005","article-title":"\u00bfEs realmente la enfermedad pulmonar obstructiva cr\u00f3nica una enfermedad progresiva?","volume":"53","author":"Torres","year":"2017","journal-title":"Arch Bronconeumol"},{"key":"2026091717071523600_aamag292-B34","author":"Vanfleteren","year":"2025"},{"key":"2026091717071523600_aamag292-B35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1164\/rccm.202201-0209PP","article-title":"Blood eosinophils and chronic obstructive pulmonary disease: a Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 review","volume":"206","author":"Singh","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026091717071523600_aamag292-B36","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13643-024-02512-5","article-title":"Barriers and enablers to the implementation of patient-reported outcome and experience measures (PROMs\/PREMs): protocol for an umbrella review","volume":"13","author":"Fontaine","year":"2024","journal-title":"Syst Rev"},{"key":"2026091717071523600_aamag292-B37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4104\/pcrj.2013.00022","article-title":"Usefulness of the COPD assessment test (CAT) in primary care","volume":"22","author":"Langhammer","year":"2013","journal-title":"Prim Care Respir J"},{"key":"2026091717071523600_aamag292-B38","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/eurpub\/ckv122","article-title":"The impact of electronic health records on healthcare quality: a systematic review and meta-analysis","volume":"26","author":"Campanella","year":"2016","journal-title":"Eur J Public Health"},{"key":"2026091717071523600_aamag292-B39","doi-asserted-by":"publisher","first-page":"1479973120964814","DOI":"10.1177\/1479973120964814","article-title":"The quality of COPD care in German general practice\u2014a cross-sectional study","volume":"17","author":"Heinm\u00fcller","year":"2020","journal-title":"Chron Respir Dis"},{"key":"2026091717071523600_aamag292-B40","doi-asserted-by":"publisher","first-page":"1479973120985594","DOI":"10.1177\/1479973120985594","article-title":"Spotlight on primary care management of COPD: electronic health records","volume":"18","author":"Harries","year":"2021","journal-title":"Chron Respir Dis"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/advance-article-pdf\/doi\/10.1093\/ajrccm\/aamag292\/68515815\/aamag292.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/212\/9\/2036\/68515815\/aamag292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/212\/9\/2036\/68515815\/aamag292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:07:23Z","timestamp":1789679243000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/212\/9\/2036\/8706700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,6,11]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajrccm\/aamag292","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,6,11]]}}}